Ts and 76/77 (98.7 ) of vaccinees who weren't subsequently infected by wildtype EBV developed
Ts and 76/77 (98.7 ) of vaccinees who weren't subsequently infected by wildtype EBV developed gp350 antibodies. The efficacy analysis consisted of following the subjects for as much as 19…